BioVaxys and SpayVac-for-Wildlife Expand License Agreement to Aquaculture Market
BioVaxys Technology Corp. and SpayVac-for-Wildlife have broadened their license agreement to include commercial aquaculture, potentially opening significant revenue opportunities in the global fish farming market through innovative fertility-control vaccine technology.
BioVaxys Technology Corp. and SpayVac-for-Wildlife have expanded their existing license agreement to include commercial aquaculture and farm-raised fish markets, potentially transforming reproductive management in the global fish farming industry.
The expanded agreement allows SpayVac to develop and market no-booster fertility-control vaccines specifically designed for aquaculture. Unlike current methods like triploidy, which involve genetic manipulation, SpayVac's approach offers a single-dose immunocontraceptive vaccine that could provide fish producers with a more scalable and cost-effective solution.
CEO Thomas D'Orazio highlighted the significance of this market expansion, noting that the approach presents a substantial addressable market for their contraceptive vaccines. The technology could revolutionize reproductive control in farmed fish, offering producers an alternative to existing genetic sterility techniques.
This strategic move significantly increases SpayVac's global revenue potential by entering the lucrative aquaculture sector. The single-dose vaccine approach could represent a more streamlined and potentially less invasive method of managing fish reproduction in commercial farming environments.
The expansion builds upon BioVaxys' existing work in developing innovative immunotherapies and demonstrates the company's commitment to exploring diverse applications for its proprietary vaccine technologies across multiple sectors.